Archive | June, 2017

RESI Testimonials – Hear from the Folks Who Attended

29 Jun

By Michael Quigley, VP of Market Research, LSN

mike-2RESI San Diego was another successful event for fundraising life science companies, investors and strategic partners. With a great deal of praise coming from those on both sides of the investment table, you can read the testimonials below to see for yourself what industry executives are saying about RESI.


Brian Frenzel, MBA: Membership Committee, Band of Angels; President, CEO and Director Tosk, Inc.

Congratulations on a great RESI meeting in San Diego last week. I have been attending biomedical conferences for longer than I’d like to admit – ABC, ACA, ACOG, ASA, ASCO, BIO, DMD, H&Q, JPM, MnM, PhRMA, and many others, some whose acronyms are slowly being lost to history.

The RESI meeting in San Diego was one of the best organized and most productive that I have ever attended. The event’s sole focus on early stage investments and fundraising along with the partnering system made it very easy to identify companies of interest and schedule meetings. RESI staff were always available to help. The energy level was very high, and I was delighted to see so many new companies, new technologies, and new investors in attendance. Not only did I fill every meeting slot, but extended it into lunch, the reception, the following day, and the following week. I am confident that several companies I met at RESI will yield new business relationships.

My hat’s off to you and the RESI staff that made it possible!

Gregory Stein MD, MBA: President and CEO Curtana Pharmaceuticals

Congratulations on running yet another successful RESI conference! I have attended several over the past 3 years and they just keep getting better. The partnering system makes it easy to identify leads and I always have a packed meeting schedule with potential investors and partners that I could not have otherwise found through the usual channels. While I did not see immediate success, you and I both know this is, in part, a numbers game and persistence pays. It has taken a lot of work, but this past March I closed with one investor group and in July I will close with another group that has committed to invest. From the recent San Diego conference, I have several new high-quality investor leads and partnering opportunities to follow-up on in the coming weeks. Given the enthusiastic response I received to Curtana’s story, I anticipate that we will continue to benefit from the relationships we have made at the RESI conferences.

Yao Ho MBA: Business Development Director LYFE Capital

Attending numerous RESI from a few years back, I can say that the events are getting increasingly better and a must go to event to meet quality companies. Attendees from the investor side has also been increasing in quantity and quality, almost feeling like a 1:1 attendee ratio. The partnering system is intuitive to use and makes identifying promising companies to meet quite easy. From the event I have met many new business relationships that I expect will flourish in not only in the business setting but also as friends. Most importantly the follow-up rate from meetings held at RESI is also quite high, proving to me that the quality and dedication of these companies are certainly a par above. The RESI team has always been helpful in addressing any concerns and helping build new leads. I am certain that we will be attending future RESI events and look forward to seeing RESI flourish. Congrats to the RESI team on making another great event!

Considerations for Pivoting Your Startup

29 Jun

By Cole Bunn, Senior Research Analyst, LSN

cole-wpAt the outset of your life science startup company, you may have great technology and a well-thought-out business plan, however oftentimes your company ends up looking much different than you had imagined. The long development timelines and capital-intensive nature of the life science sector usually doesn’t allow for much in terms of testing product/market fit, meaning these startups had better have done extensive research on their target market – various stakeholders, investor sentiment, market dynamics, end user and patient preferences, regulatory environment for target indication, and other important factors. However, at times even the most prepared company may encounter the need to pivot.

In the startup/venture tech community, the term ‘pivot’ is often used to describe the need to be open to strategically changing the company’s direction in response to market feedback. Even in life sciences, it’s essential for entrepreneurs to stay ahead of industry and regulatory developments and continually scrutinize feedback from potential partners and investors. This allows a company to more easily identify the reason their message is not gaining traction with investors and adjust accordingly, whether it be positioning, strategy, product/offering, or their business model.

Pivoting doesn’t necessarily need to be a complete shift to a new market or product, although that is what typically comes to mind. Relatively small tweaks or adjustments can have a significant impact, and might help reinvigorate your campaign.

Aligning Strategy with Market Drivers

While your product may be better, faster, cheaper than the standard-of-care, if you’re not correctly positioning your company with the big picture, you may run into some problems garnering interest in your venture as investors/partners might overlook how you fit in and thus your company’s potential. As an example, a medical device company in the urology space struggling to gain interest in their financing round saw a significant uptick in interest after rebranding their company as an infection control company rather than simply a medical device company. As the U.S. healthcare system is making changes to how healthcare services are delivered and hospitals are paid, the ACA made it such that hospitals are penalized for not meeting standards on hospital-acquired infection rates. Pivoting to better address this development allowed the company to clearly show how they could provide solutions to a defined problem as opposed to being another medical device company with a better product.

Sidestepping Negative Perceptions

Another potential roadblock is an unfavorable outlook on your technology type or indication. Regardless of how innovative your technology is and how compelling your data may be, if you’re targeting a highly-crowded space or an indication with a low success rate, such as most neuro indications, potential investors may write you off before even hearing the pitch. This may require you to completely rework your messaging so that you quickly and clearly point out the key differentiators of your technology and accentuate ways in which your mitigating the specific risks that have plagued similar, failed approaches. Additionally, it’s important that you pursue someone at the firm who has expertise in your specific area, if possible. These individuals are much more likely to take a serious look at your project rather than immediately shutting you down based on something such as an aversion to the space you’re in.

The bottom line is that the market dictates everything, and not properly addressing or even ignoring what it’s telling you won’t help you succeed. It’s important to note the cause of each pushback you receive; if you’re repeatedly receiving pushback on the same issues, it may be possible to make an adjustment, or if necessary a complete pivot, before you’ve depleted all your resources pursuing an un-fundable opportunity. That said, while not completely disregarding any input, it is advisable to give less weight to the declines from groups who have no expertise in your specific field as they may not have thoroughly understood or evaluated your proposal.

It’s critical to be completely in tune with new developments such as regulatory changes or moves by competitors; understanding what these changes mean for your company could provide opportunities for a pivot. It’s also important to be vigilant in documenting and evaluating the feedback you receive; this feedback could aid you in determining when and how to change direction to keep moving forward.

Hot Investor Mandate 1: Singapore Fund Looks to US & Europe for Commercial-Ready Medtech, Synthetic Biology & HCIT

29 Jun

A venture capital firm based in Singapore, with additional office in Silicon Valley, makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia and/or Singapore. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking medical devices, synthetic biology
and HCIT. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.

The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: